Your browser doesn't support javascript.
loading
An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.
Lin, Jing; Liu, Jun; Hao, Shi-Guang; Lan, Bin; Zheng, Xiao-Bin; Xiong, Jia-Ni; Zhang, Ying-Qian; Gao, Xuan; Chen, Chuan-Ben; Chen, Ling; Huang, Yu-Fang; Luo, Hong; Yi, Yu-Ting; Yi, Xin; Lu, Jian-Ping; Zheng, Xiong-Wei; Chen, Gang; Wang, Xue-Feng; Chen, Yu.
Afiliación
  • Lin J; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Liu J; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Hao SG; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Lan B; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Zheng XB; Geneplus-Beijing Institute, Beijing, China.
  • Xiong JN; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Zhang YQ; Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Gao X; Fujian Provincial Key Laboratory of Tumor Biotherapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Chen CB; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Chen L; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Huang YF; Geneplus-Beijing Institute, Beijing, China.
  • Luo H; State Key Laboratory of Microbial Resources, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
  • Yi YT; Department of Translational Medicine, GenePlus- Shenzhen Clinical Laboratory, ShenZhen, China.
  • Yi X; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Lu JP; Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Zheng XW; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Chen G; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Wang XF; Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Chen Y; Cancer Bio-immunotherapy Center, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Front Immunol ; 13: 1022598, 2022.
Article en En | MEDLINE | ID: mdl-36505399
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Vacunas contra el Cáncer / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Vacunas contra el Cáncer / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article